Free Trial
NYSE:UPC

Universe Pharmaceuticals (UPC) Stock Price, News & Analysis

Universe Pharmaceuticals logo
$1.79 -0.06 (-3.24%)
(As of 11/21/2024 ET)

About Universe Pharmaceuticals Stock (NYSE:UPC)

Key Stats

Today's Range
$1.71
$1.85
50-Day Range
$0.14
$8.16
52-Week Range
$1.71
$64.80
Volume
39,593 shs
Average Volume
75,747 shs
Market Capitalization
$429,600.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

Receive UPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Universe Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

UPC Stock News Headlines

Universe Pharmaceuticals Inc trading halted, news pending
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Universe Pharmaceuticals announces share consolidation
Universe Pharmaceuticals Faces Nasdaq Compliance Challenge
See More Headlines

UPC Stock Analysis - Frequently Asked Questions

Universe Pharmaceuticals' stock was trading at $30.15 on January 1st, 2024. Since then, UPC stock has decreased by 94.1% and is now trading at $1.79.
View the best growth stocks for 2024 here
.

Universe Pharmaceuticals's stock reverse split before market open on Wednesday, November 13th 2024. The 1-15 reverse split was announced on Wednesday, November 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Universe Pharmaceuticals (UPC) raised $30 million in an initial public offering (IPO) on Tuesday, March 23rd 2021. The company issued 5,000,000 shares at $5.00-$7.00 per share. Univest Securities, LLC acted as the underwriter for the IPO.

Top institutional investors of Universe Pharmaceuticals include MML Investors Services LLC (6.46%).

Shares of UPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Universe Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF) and General Electric (GE).

Company Calendar

Today
11/22/2024
Next Earnings (Estimated)
2/04/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
225
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.31 million
Book Value
$163.51 per share

Miscellaneous

Free Float
103,000
Market Cap
$429,600.00
Optionable
Not Optionable
Beta
1.54
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSE:UPC) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners